News

6 June 2023
Vaxxas Announces Interim Phase I Study Results for First Needle-Free HD-MAP COVID-19 Vaccine
Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology. The COVID-19 vaccine patch is based upon HD-MAP delivery of a SARS-CoV-2 spike subunit vaccine candidate from The […]
6 June 2023
Vaxxas Appoints Dr. Rochelle Chaiken as Chief Medical Officer
Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform technology, today announced the appointment of Dr. Rochelle Chaiken, as Chief Medical Officer. Dr. Chaiken joins Vaxxas following a 23-year career at Pfizer, bringing extensive experience designing and executing late-stage clinical trials and successfully launching new products in markets. Reporting to Vaxxas Chief Executive Officer […]
2 June 2023
Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity
BOSTON–(BUSINESS WIRE)–Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered first-in-class gut-targeted polymer therapies, today announced clinical progress with its lead candidate, GLY-200, for the treatment of type 2 diabetes (T2D) and obesity. Data across completed Phase 1 and Phase 2a clinical trials demonstrated that the novel mechanism of GLY-200 offers […]
2 June 2023
Aravax doses first patient in Phase 2 peanut allergy clinical trials
The first patient has been dosed in a Phase 2 study (AVX-201) being run by biotechnology company Aravax, which is developing the novel therapy PVX108 for the safe and convenient treatment of peanut allergy. The study is being conducted under a U.S. FDA Investigational New Drug Application. Allergy clinical trial centres across Victoria, South Australia, […]
24 May 2023
Nineteen groundbreaking biotech projects selected for national incubator
CUREator, Australia’s national biotech incubator, today announces its second round of funding, awarding $12 million to 19 projects targeting global health challenges   including advances in treatment for lupus, motor neurone disease, brain and ovarian cancer, and inflammatory bowel disease. CUREator is delivered through an initial $40m in funding from the Federal Government’s Medical Research Future […]
22 May 2023
EBR Systems meets endpoints early in pivotal SOLVE-CRT trial: paves way for FDA approval application and commercialisation
EBR Systems, Inc. (ASX: EBR), the medical device company developing wireless cardiac pacing systems, has met its primary safety and efficacy endpoints in its pivotal SOLVE-CRT trial of the WiSE® Cardiac Resynchronization Therapy (CRT) System. EBR Systems’ WiSE CRT System is on track for the Premarket Approval (PMA) application to the Food and Drug Administration […]
3 May 2023
Healthcare Veteran, Zach Henderson to lead Global Kinetics as CEO
Charlotte, US & Melbourne, Australia – May 3, 2023, Global Kinetics, the global leader in digital health solutions for neurological conditions, today announced the appointment of Zach Henderson as its new Chief Executive Officer. Zach will also join the Board of Directors. Zach joins Global Kinetics with over 25 years of healthcare software and big data experience […]
21 March 2023
Brandon BioCatalyst, in partnership with ANDHealth, selected by the Federal Government to deliver $50m BioMedTech Incubator Program
Federal investment creates a combined funding capability of $115m across programs managed by Brandon BioCatalyst & ANDHealth. Brandon BioCatalyst, in partnership with ANDHealth, has been selected by the Federal Government to deliver the $50m BioMedTech Incubator (BMTI) program. The investment, from the $20b Medical Research Future fund (MRFF), substantially increases the grant funding available through existing Brandon […]
10 March 2023
Aravax initiates Phase 2 peanut allergy clinical trials in Australia
Aravax, a clinical stage biotechnology company developing next generation immunotherapies which are safe, convenient, and precisely targeted, today announces it has initiated the first clinical trial sites in Australia for AVX-201 in Australia, a Phase 2 trial of PVX108 for the treatment of peanut allergy. Aravax received the green light for its Investigational New Drug […]
9 March 2023
Tech entrepreneur amongst stellar cohort in latest Women in Leadership Development (WILD) Program, which is expanding with new Federal investment
The WILD Women team, supported by Brandon BioCatalyst, receives further funding to expand successful Science, Technology, Engineering and Mathematics (STEM) women’s leadership program. Women represent 27 per cent of the STEM workforce but hold just 8 per cent of CEO roles, less than the 20 per cent figure across the broader economy – Workplace Gender […]
14 February 2023
Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study
Post hoc analyses found a statistically significant reduction in the duration of flu infection and a dose-related trend toward a reduction in symptom duration. These results support the further clinical development of INNA-051 to mitigate the impact of natural infection by respiratory viruses such as SARS-CoV-2 and its variants: influenza, RSV, and the common cold, in […]
10 February 2023
Vaxxas initiates Phase I study for needle-free seasonal influenza vaccine delivered using High-Density Microarray Patch (HD-MAP)
Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate delivered using Vaxxas’ proprietary needle-free vaccine technology, the high-density microarray patch (HD-MAP). The Phase I clinical trial will assess the safety, tolerability, and immunogenicity of […]
6 February 2023
Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
Data from Certa Therapeutics’ Phase 2 clinical trial with development candidate FT011 demonstrates clinically meaningful improvements for more than 60 percent of patients with scleroderma after 12 weeks of treatment; Clinically meaningful improvements were reported in CRISS (the key composite endpoint for systemic sclerosis) lung function, SHAQ-DI and Physician Global Assessment; The trial results also […]
19 January 2023
Coming in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access
CEPI to provide up to USD4.3 million (AUD6.4 million) to Vaxxas to advance development of its high-density microarray patch for mRNA vaccines. Vaxxas’ vaccine-delivery platform could improve access to mRNA vaccines by removing the need for frozen storage, enabling easier distribution and offering accurate and safe dosing with minimal waste. CEPI, the Coalition for Epidemic […]
10 January 2023
ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051
Goal is to add new medical countermeasure (MCM) against known and emerging viral respiratory threats Clinical-stage pharmaceutical company ENA Respiratory has been awarded a $4.38 million USD agreement from the U.S. Department of Defense (DoD) to support ongoing research and development of INNA-051, a clinical stage first-in-class broadspectrum antiviral innate immunomodulator, administered intranasally for the […]

Contact Us

Melbourne

Level 9, 31 Queen Street

Melbourne VIC 3000

Phone +61 3 9657 0700

Email: info@brandoncapital.com.au

Sydney

Suite 2.05, 1 York Street

Sydney NSW 2000

Phone +61 2 8227 7080

Email: info@brandoncapital.com.au

San Francisco

Brandon Capital LLC

1 Letterman Ave, Suite C3-330

San Francisco, CA 94129

Phone +61 3 9657 0700

Email: info@brandoncapital.com.au

London

The Gridiron Building, 1 Pancras Square

Kings Cross, London N1C 4AG

United Kingdom

Email: info@brandoncapital.com.au

For media inquiries, contact

Ciara Byrne

cb@manacommunications.com

+61 41 3519 430


Caleb Hulme-Moir

chm@manacommunications.com

+64 20 698 065

© Copyright 2023 Brandon Capital Partners

Brandon Capital is aware of scammers impersonating us - offering jobs and asking for bank details. We do not offer employment or ask for banking details via SMS, websites or phone calls. Do not provide any details and report to the relevant authorities in your location.